SCHEMBL20580266

SCHEMBL20580266

Cc1ccccc1-c1nc2ccccn2c1C(=O)OCC(F)(F)F

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 2/20 0.57
▸ CYP2C9 P11712 2/20 0.57
▸ CYP2C19 P33261 2/20 0.57
▸ SMN1; SMN2 Q16637 1/20 0.57
▸ MAPK1 P28482 2/20 0.52
▸ DPP4 P27487 1/20 0.49
▸ ALDH1A1 P00352 7/20 0.47
▸ RXFP1 Q9HBX9 1/20 0.47
▸ KMT2A Q03164 3/20 0.44
▸ MEN1 O00255 1/20 0.44
▸ CYP3A4 P08684 1/20 0.44
▸ CYP2D6 P10635 1/20 0.44
▸ NPC1 O15118 2/20 0.43
▸ RAB9A P51151 2/20 0.43
▸ NPSR1 Q6W5P4 2/20 0.43
▸ KDM4E B2RXH2 2/20 0.43
▸ HSD17B10 Q99714 1/20 0.43
▸ HPGD P15428 1/20 0.43
▸ TSHR P16473 1/20 0.42
▸ DAPK3 O43293 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20579832 0.84 CYP1A2 (0.66) CYP1A2CYP2C9CYP2C19SMN1; SMN2MAPK1
SCHEMBL20579758 0.84 CYP1A2 (0.72) CYP1A2CYP2C9CYP2C19SMN1; SMN2MAPK1
SCHEMBL20579760 0.83 MAPK1 (0.74) CYP1A2CYP2C9CYP2C19SMN1; SMN2MAPK1
SCHEMBL20579820 0.82 CYP1A2 (0.62) CYP1A2CYP2C9CYP2C19SMN1; SMN2MAPK1
SCHEMBL21097067 0.81 SMN1; SMN2 (0.60) CYP1A2CYP2C9CYP2C19SMN1; SMN2MAPK1
SCHEMBL20579799 0.81 SMN1; SMN2 (0.60) CYP1A2CYP2C9CYP2C19SMN1; SMN2MAPK1
SCHEMBL20579783 0.80 CYP1A2 (0.60) CYP1A2CYP2C9CYP2C19SMN1; SMN2MAPK1
SCHEMBL20580270 0.77 SMN1; SMN2 (0.55) CYP1A2CYP2C9CYP2C19SMN1; SMN2MAPK1
SCHEMBL14740847 0.76 CYP1A2 (0.70) CYP1A2CYP2C9CYP2C19SMN1; SMN2MAPK1
SCHEMBL20579779 0.76 CYP1A2 (0.77) CYP1A2CYP2C9CYP2C19SMN1; SMN2MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10323033-B2 Imidazo[1,2-A]pyridine-3-carboxylate derivative and preparation method thereof KNU-INDUSTRY COOPERATION FOUNDATION (KR) 2019-06-18 — — US disclosed
US-10323033-B2 Imidazo[1,2-A]pyridine-3-carboxylate derivative and preparation method thereof KNU-INDUSTRY COOPERATION FOUNDATION (KR) 2019-06-18 — — US disclosed
US-20180354948-A1 IMIDAZO[1,2-A]PYRIDINE-3-CARBOXYLATE DERIVATIVE AND PREPARATION METHOD THEREOF KNU-INDUSTRY COOPERATION FOUNDATION (KR) 2018-12-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180354948-A1 IMIDAZO[1,2-A]PYRIDINE-3-CARBOXYLATE DERIVATIVE AND PREPARATION METHOD THEREOF AZI2, AOC3, AOC2 CYP1A2 10/4885CYP2C9 219/4885CYP2C19 140/4885
US-10323033-B2 Imidazo[1,2-A]pyridine-3-carboxylate derivative and preparation method thereof AZI2, AOC3, AOC2 CYP1A2 10/4885CYP2C9 219/4885CYP2C19 140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback